138 related articles for article (PubMed ID: 34942512)
1. PD-L1 expression is regulated by microphthalmia-associated transcription factor (MITF) in nodular melanoma.
Vučinić D; Grahovac M; Grahovac B; Vitezić BM; Kovač L; Belušić-Gobić M; Zamolo G
Pathol Res Pract; 2022 Jan; 229():153725. PubMed ID: 34942512
[TBL] [Abstract][Full Text] [Related]
2. The tumor suppressor HINT1 regulates MITF and β-catenin transcriptional activity in melanoma cells.
Genovese G; Ghosh P; Li H; Rettino A; Sioletic S; Cittadini A; Sgambato A
Cell Cycle; 2012 Jun; 11(11):2206-15. PubMed ID: 22647378
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF.
Wellbrock C; Rana S; Paterson H; Pickersgill H; Brummelkamp T; Marais R
PLoS One; 2008 Jul; 3(7):e2734. PubMed ID: 18628967
[TBL] [Abstract][Full Text] [Related]
4. Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations.
Chraybi M; Abd Alsamad I; Copie-Bergman C; Baia M; André J; Dumaz N; Ortonne N
Hum Pathol; 2013 Sep; 44(9):1902-11. PubMed ID: 23664541
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
Kundu A; Quirit JG; Khouri MG; Firestone GL
Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
[TBL] [Abstract][Full Text] [Related]
6. Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit.
Sabbah M; Krayem M; Najem A; Sales F; Miller W; Del Rincon S; Awada A; Ghanem GE; Journe F
Mol Cancer Res; 2021 Jul; 19(7):1221-1233. PubMed ID: 33741716
[TBL] [Abstract][Full Text] [Related]
7. Role of microphthalmia transcription factor (Mitf) in melanoma differentiation.
Lekmine F; Chang CK; Sethakorn N; Das Gupta TK; Salti GI
Biochem Biophys Res Commun; 2007 Mar; 354(3):830-5. PubMed ID: 17266927
[TBL] [Abstract][Full Text] [Related]
8. miR-211 and MITF modulation by Bcl-2 protein in melanoma cells.
De Luca T; Pelosi A; Trisciuoglio D; D'Aguanno S; Desideri M; Farini V; Di Martile M; Bellei B; Tupone MG; Candiloro A; Regazzo G; Rizzo MG; Del Bufalo D
Mol Carcinog; 2016 Dec; 55(12):2304-2312. PubMed ID: 26599548
[TBL] [Abstract][Full Text] [Related]
9. Comparative investigation of cell cycle and immunomodulatory genes in mucosal and cutaneous melanomas: Preliminary data suggest a potential promising clinical role for p16 and the PD-1/PD-L1 axis.
Wrede N; Hoffmann I; Vollbrecht C; Koch I; Wolkenstein P; Klauschen F; Capper D; von Laffert M; Jurmeister P
Pathol Res Pract; 2022 Jan; 229():153689. PubMed ID: 34844086
[TBL] [Abstract][Full Text] [Related]
10. Role of microRNA-182 in posterior uveal melanoma: regulation of tumor development through MITF, BCL2 and cyclin D2.
Yan D; Dong XD; Chen X; Yao S; Wang L; Wang J; Wang C; Hu DN; Qu J; Tu L
PLoS One; 2012; 7(7):e40967. PubMed ID: 22848417
[TBL] [Abstract][Full Text] [Related]
11. Pro-survival role of MITF in melanoma.
Hartman ML; Czyz M
J Invest Dermatol; 2015 Feb; 135(2):352-358. PubMed ID: 25142731
[TBL] [Abstract][Full Text] [Related]
12. Dermatofibrosarcoma protuberans: A retrospective study of clinicopathologic features and related Akt/mTOR, STAT3, ERK, cyclin D1, and PD-L1 expression.
Park S; Cho S; Kim M; Park JU; Jeong EC; Choi E; Park JH; Lee C; Chang MS
J Am Acad Dermatol; 2018 Nov; 79(5):843-852. PubMed ID: 29792909
[TBL] [Abstract][Full Text] [Related]
13. Frequent mutations in the MITF pathway in melanoma.
Cronin JC; Wunderlich J; Loftus SK; Prickett TD; Wei X; Ridd K; Vemula S; Burrell AS; Agrawal NS; Lin JC; Banister CE; Buckhaults P; Rosenberg SA; Bastian BC; Pavan WJ; Samuels Y
Pigment Cell Melanoma Res; 2009 Aug; 22(4):435-44. PubMed ID: 19422606
[TBL] [Abstract][Full Text] [Related]
14. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.
Garraway LA; Widlund HR; Rubin MA; Getz G; Berger AJ; Ramaswamy S; Beroukhim R; Milner DA; Granter SR; Du J; Lee C; Wagner SN; Li C; Golub TR; Rimm DL; Meyerson ML; Fisher DE; Sellers WR
Nature; 2005 Jul; 436(7047):117-22. PubMed ID: 16001072
[TBL] [Abstract][Full Text] [Related]
15. Activation of the long terminal repeat of human endogenous retrovirus K by melanoma-specific transcription factor MITF-M.
Katoh I; Mírová A; Kurata S; Murakami Y; Horikawa K; Nakakuki N; Sakai T; Hashimoto K; Maruyama A; Yonaga T; Fukunishi N; Moriishi K; Hirai H
Neoplasia; 2011 Nov; 13(11):1081-92. PubMed ID: 22131883
[TBL] [Abstract][Full Text] [Related]
16. TYRP1 mRNA level is stable and MITF-M-independent in drug-naïve, vemurafenib- and trametinib-resistant BRAF
Hartman ML; Czyz M
Arch Dermatol Res; 2020 Jul; 312(5):385-392. PubMed ID: 31624899
[TBL] [Abstract][Full Text] [Related]
17. Microphthalmia-associated transcription factor gene amplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response.
Ugurel S; Houben R; Schrama D; Voigt H; Zapatka M; Schadendorf D; Bröcker EB; Becker JC
Clin Cancer Res; 2007 Nov; 13(21):6344-50. PubMed ID: 17975146
[TBL] [Abstract][Full Text] [Related]
18. Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy.
Wellbrock C; Arozarena I
Pigment Cell Melanoma Res; 2015 Jul; 28(4):390-406. PubMed ID: 25818589
[TBL] [Abstract][Full Text] [Related]
19. Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.
Yang S; Leone DA; Biswas A; Deng A; Jukic D; Singh R; Sundram U; Mahalingam M
Hum Pathol; 2018 Dec; 82():206-214. PubMed ID: 30120967
[TBL] [Abstract][Full Text] [Related]
20. Regulatory and functional connection of microphthalmia-associated transcription factor and anti-metastatic pigment epithelium derived factor in melanoma.
Fernández-Barral A; Orgaz JL; Baquero P; Ali Z; Moreno A; Tiana M; Gómez V; Riveiro-Falkenbach E; Cañadas C; Zazo S; Bertolotto C; Davidson I; Rodríguez-Peralto JL; Palmero I; Rojo F; Jensen LD; del Peso L; Jiménez B
Neoplasia; 2014 Jun; 16(6):529-42. PubMed ID: 25030625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
